Inc), the authors quantified the same biomarkers with comparable results, demonstrating a significant decrease in total α-synuclein in PD patients (7.104 ± 5.122 pg/mL) compared to the control group (28.444 ± 25.877 pg/mL), a significant elevation in oligomeric α-synuclein in PD sufferers (0.893 ± 1.949 ng/mL) compared to healthy subjects (0.217 ± 0.191 ng/mL), and a significantly elevated ratio between these biomarkers (PD: 0.235 ± 0.793 vs. control: 0.0126 ± 0.0079). The gene discussed is SNCA; the disease is Parkinson disease.